Skip to content

Antibody from Tanzanian woman suppresses almost all tested HIV variants including resistant viruses in pre-clinical study

Molecular model representing the precise area of contact between 04_A06 and the CD4 binding site of the gp120 glycoprotein.

Antibodies that ‘wait and pounce’ generated by promising HIV vaccine candidate

Dr Wilton Williams at IAS 2023. Photo ©Conor Ashleigh/IAS

Revolutionary HIV vaccine that ‘trains’ the immune system passes its first hurdle

Gustavo Fring/Pexels

Do broadly neutralising antibodies really have a future in treating HIV?

thekopmylife/Shutterstock.com

The paediatric drug pipeline should include improvements to current HIV treatment, long-acting formulations and antibodies

UNDP South Sudan/Brian Sokol. Creative Commons licence. Image for illustrative purposes only.

Giving antibodies to prevent vertical transmission in Africa would be cost-effective or even save money, study finds

Image by USAID | Southern Africa. Creative Commons licence.

HIV vaccines and immunotherapies “would be further along” if they had the resources of COVID-19, says leading antibody researcher

Professor Lynn Morris presenting to IAS 2021.

Where next for HIV vaccines and antibody therapies?

Dr Mark Feinberg, President of IAVI

Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’

Professor Larry Corey, principal researcher of the AMP studies, speaking at HIVR4P